Abstract v-Raf murine sarcoma viral oncogene homolog B (BRAF)-mutated (MT) metastatic colorectal cancer (mCRC) has a poor prognosis. We report real-world data on treatment and survival of these patients, compared with an age and sex-matched control group. We found that progression-free survival is poor after first-line progression. Recruitment to clinical trials is recommended to improve outcomes in BRAF-MT mCRC. Background: Somatic v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation, present in approximately 10% of metastatic colorectal cancer (mCRC) cases, is associated with poor prognosis. Patient outcome outside of clinical trials has only been reported in small series. We report real-world data on treatment and survival for BRAFmutated (MT) patients at a single tertiary center, compared with a matched BRAF wild type (WT) control group. Patients and Methods: All colorectal cancer patients tested for BRAF mutation, from October 2010 to November 2014 were identified. BRAF-MT mCRC cases were compared with an age and sex-matched BRAF-WT control group. Clinicopathological data were collected and survival calculated using the KaplaneMeier method and comparisons made using Cox regression. Results: Forty-three of 503 patients (8.5%) tested had BRAF-MT mCRC and were compared with 88 BRAF-WT controls. Median overall survival (mOS) was 18.2 months for BRAF-MT and 41.1 months for BRAF-WT mCRC patients (hazard ratio, 2.74; 95% confidence interval, 1.60-4.70; P < .001). Progression-free survival for BRAF-MT and WT patients, respectively, was: 8.1 months versus 9.2 months (P ¼ .571) first-line, 5.5 months versus 8.3 months (P ¼ .074) second-line, and 1.8 months versus 5.6 months (P ¼ .074) third-line. Treatment using sequential fluoropyrimidine-based doublet chemotherapy was similar between both groups. Anti-epidermal growth factor receptor (EGFR) therapy was mainly given third-line with progressive disease in 90% (n ¼ 9 of 10) of BRAF-MT patients at first restaging. Conclusion: In this case-control study, the poor mOS of BRAF-MT mCRC was associated with reduced treatment benefit beyond first-line. Sequential doublet chemotherapy remains a reasonable option in appropriately selected patients. BRAF-MT patients did not benefit from anti-EGFR therapy in this study. Recruitment to clinical trials is recommended to improve outcomes in BRAF-MT mCRC.
Introduction
Globally metastatic colorectal cancer (mCRC) is the third leading cause of cancer mortality and a major cause of cancer morbidity. 1 Implementation of screening, such as the UK Bowel Cancer Screening Program, has improved detection of early stage disease. 2 However, on a population basis approximately 20% of patients still present with advanced disease 3, 4 and further patients develop metastatic recurrence. Despite advances in surgery, locoregional therapy (ablation, embolization, and radiotherapy) and systemic therapy, 5-year overall survival (OS) for stage IV disease remains poor at 8% in the United Kingdom (UK). 3 There is thus, a great unmet need for improved treatments for this disease. In recent years, significant advances have been made in understanding the molecular pathology and genetic aberrations involved in colorectal cancer (CRC). This has helped stratify patients for selected treatments, including exclusion from anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) treatment in rat sarcoma viral oncogene (RAS)-mutant mCRC. Furthermore, in stage II colon cancer retrospective data have shown that deficient mismatch repair prognosticates improved survival and lack of benefit from adjuvant chemotherapy. 5 Among these discoveries, somatic mutation in the proto-oncogene, BRAF, has emerged as an important biomarker associated with a poor prognosis in mCRC. 6 The v-Raf murine sarcoma viral oncogene homolog B (BRAF) oncogene encodes a signaling protein within the mitogen-activated protein kinase (MAPK) pathway; a key regulator of cellular proliferation and survival. 7, 8 Activating BRAF mutations are seen in approximately 10% of all cases of mCRC and result in constitutive activation of the MAPK pathway, leading to aggressive tumor biology and poor prognosis. 9 Most BRAF gene mutations lead to a single amino acid substitution at position 600 of exon 15, with replacement of valine for glutamic acid (V600E). 10 BRAF-mutated (MT) mCRC is associated with distinct clinical characteristics, including female sex, older age (older than 70 years), right-sided primary tumor location, peritoneal metastases, and DNA mismatch repair (MMR) deficiency. 9, 11, 12 Median OS (mOS) for BRAF-MT mCRC patients receiving sequential fluoropyrimidine-based doublet chemotherapy, within the context of clinical trials, is poor at 10 to 15 months. 6, 13 Triplet chemotherapy with or without use of mAbs has been suggested as an approach to improve response rates and survival in molecularly unselected patients. The use of such an aggressive upfront treatment strategy has the potential to mitigate the poor prognosis of BRAF-MT tumors. Loupakis et al reported a mOS of 24.1 months in a single-arm phase II trial of 15 BRAF-MT mCRC patients treated with first-line folinic acid, fluorouracil, oxaliplatin, irinotecan (FOLFOXIRI)-bevacizumab. 14 The same group also conducted the phase III combination chemotherapy and bevacizumab as first-line therapy in metastatic colorectal cancer (TRIBE) trial, which recently reported a trend toward improved OS in the subgroup of BRAF-MT patients (n ¼ 28) treated with FOLFOXIRI-bevacizumab compared with fluorouracil, leucovorin, and irinotecan (FOL-FIRI)-bevacizumab, achieving a mOS of 19.0 months in the experimental arm. 15 Both studies included only small numbers of selected BRAF-MT patients, all with good performance status (PS). The superiority and tolerability of this regimen in the general population of BRAF-MT patients is unclear.
Another area of uncertainty is the role of BRAF mutations as a negative predictive biomarker for benefit from anti-EGFR therapy. Two recent meta-analyses have reviewed this 16, 17 and there is increasing consensus that BRAF-MT patients are unlikely to benefit from anti-EGFR therapy. 18 Only a small number of studies have reported on survival outcomes and treatment regimens for BRAF-MT mCRC patients outside of the clinical trial setting. 19 In this retrospective study, we provide real-world data on outcomes for patients with BRAF-MT mCRC, treated with sequential therapy at a single high-volume tertiary center and compare outcomes with a matched control group of BRAF-wild type (WT) patients.
Patients and Methods
All patients with CRC who had been tested for somatic BRAF mutations from October 2010 when routine testing was introduced, through to November 2014 were identified from the Royal Marsden Hospital (RMH) molecular diagnostic service.
Formalin-fixed paraffin-embedded tumor samples were tested for BRAF exon 15 mutations in a Clinical Pathology Accreditation-certified laboratory using either custom amplicon-based next-generation sequencing (TSCA; Illumina, Cambridge, UK) or capillary electrophoresis single-strand conformation analysis. All samples were also tested for RAS gene mutations. Up until October 2011, only exon 2 (codons 12 and 13) of Kirsten rat sarcoma viral oncogene (KRAS) was tested (Therascreen KRAS kit; Qiagen, Hilden, Germany). From November 2011 to September 2013, exons 2 (codons 12 and 13) and 3 (codon 61) of KRAS were tested (COBAS KRAS kit; Roche Molecular Diagnostics, Pleasanton, CA). From October 2013 onward, exons 2, 3, and 4 (codons 117 and 146) of KRAS and neuroblastoma rat sarcoma viral oncogene (NRAS) were tested (colorectal NGS assay, Illumina).
Only patients with stage IV disease were included in the analysis and each BRAF-MT patient was matched to 2 BRAF-WT patients, according to age and sex. Age matching was performed using age group categories (50 years or younger, older than 50 and up to 65 years, and older than 65 years).
For each patient, data including demographic and tumor characteristics and treatment regimens were retrospectively collected using the RMH electronic patient record.
Statistical Analysis
Comparisons of clinical characteristics and treatment between BRAF-MT and WT patients were made using the c 2 , ManneWhitney, and KolmogoroveSmirnov equality of distribution test. OS was defined as beginning on the date of diagnosis of advanced disease to death from any cause. Progression-free survival (PFS) was defined as beginning on the date of first treatment to disease progression or death. OS and PFS were calculated using the KaplaneMeier method and comparisons made using Cox regression. Alive patients were censored at the date of last follow-up. Hazard ratios (HRs) with 95% confidence intervals (CIs) were reported and a P value of < .05 was considered significant. Characteristics associated with survival were investigated using Cox regression univariate analysis. Disease control rate (DCR) was defined as the proportion of patients who achieved complete response, partial response, or stable disease at first restaging and comparisons were made using the c 2 test.
Approval for this study was obtained from the institution's Research & Development Department.
Results

Patient Characteristics
Five hundred three patients were tested for somatic BRAF mutation over the study period. Of those patients, 12% (59 of 503)
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Treatment and Survival in BRAF-Mutated mCRC had BRAF-MT tumors. This consisted of 16 with early stage, 16 with metastatic recurrence, and 27 with de novo metastatic disease, giving a total of 43 (8.5%) BRAF-MT mCRC patients. Three hundred twenty-two patients had BRAF-WT mCRC. Patients with early stage disease were excluded from further analysis.
The median age of mCRC patients was 70 (range, 29-85) years in the BRAF-MT group compared with 64 (range, 25-90) years in all 322 BRAF-WT patients (P ¼ .249). BRAF-MT mCRC was significantly associated with female sex. Female patients accounted for 63% (n ¼ 27 of 43) and 37% (n ¼ 118 of 332) of BRAF-MT and BRAF-WT patients, respectively (P ¼ .001).
The 43 BRAF-MT mCRC patients were matched according to age and sex to 88 BRAF-WT mCRC patients and only these patients were included in further analysis (initially 44 BRAF-MT mCRC patients were identified, however 1 case was a duplicate record and was excluded).
The primary tumor had been used for BRAF mutation analysis in 81% (n ¼ 35 of 43) of BRAF-MT patients and 91% (n ¼ 80 of 88) of BRAF-WT patients. The remaining cases were tested using tissue from a metastatic site.
Ninety-eight percent (n ¼ 42 of 43) of BRAF-MT tumors carried the V600E mutation and 1 tumor carried an R603Q mutation. BRAF mutation and RAS mutation were mutually exclusive, except in 1 tumor that had a simultaneous NRAS mutation. In the BRAF-WT group, 35% (n ¼ 31 of 88) had RAS-MT tumors.
BRAF-MT patients had significantly higher rates of right-sided primary tumor location (P ¼ .003), peritoneal metastases (P < .001), and MMR deficiency (P ¼ .001) but a lower rate of oligometastatic disease (P ¼ .038) compared with BRAF-WT patients ( Table 1) .
Treatment of Advanced Disease
The median number of lines of systemic treatment received was 2, for BRAF-MT as well as BRAF-WT patients (range, 0-4 for both).
For BRAF-MT and BRAF-WT patients respectively, 91% (n ¼ 39 of 43) and 97% (n ¼ 85 of 88) received first-line systemic therapy, whereas in the second-line setting this was reduced to 51% (n ¼ 22 of 43) and 58% (n ¼ 51 of 88), respectively, and by the third-line setting only 26% (n ¼ 11 of 43) and 26% (n ¼ 23 of 88) received systemic therapy ( Table 2) .
The median number of cycles of therapy received was similar between BRAF-MT and BRAF-WT patients in the first-line (8 vs. 7 cycles; range, 1-20 vs. 1-18) and second-line (8 vs. 9 cycles; range, 1-24 vs. 1-27), but in the third-line setting BRAF-MT patients received a lower median number of cycles (3 vs. 7 cycles; range, 1-8 vs. 2-24) but this was not statistically significant (P ¼ .206).
For BRAF-MT as well as WT patients, in the first-and secondline settings, doublet fluoropyrimidine-based chemotherapy with or without anti-vascular endothelial growth factor (VEGF) mAbs was the most common regimen. There was limited use of anti-EGFR agents in the first-line setting, but its use increased progressively in the second-and in particular third-line setting ( Table 2) .
There was a trend toward lower rates of radical metastasectomy in BRAF-MT compared with BRAF-WT patients, however, this did not reach statistical significance (12% [n ¼ 5 of 43] vs. 24% [n ¼ 21 of 88], respectively; P ¼ .099). 
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Survival Outcomes in Advanced Disease
Median progression free survival (mPFS) in the first-line setting was not significantly different between BRAF-MT and BRAF-WT patients at 8.1 months and 9.2 months, respectively (HR, 1.14; 95% CI, 0.873-1.77; P ¼ .571). However, in subsequent treatment lines mPFS declined for BRAF-MT patients decreasing to 5.5 months in the second-line and 1.8 months in the third-line setting, which approached statistical significance compared with BRAF-WT patients, who had a mPFS of 8.3 and 5.6 months, respectively, in the second-and third-line setting (P ¼ .074 for both; Table 3 ).
Disease control rate was similar between BRAF-MT and BRAF-WT patients in the first and second-line settings. However, in the third-line setting, DCR was lower for BRAF-MT patients and approached statistical significance (DCR, 0% [n ¼ 0 of 10] in BRAF-MT vs. 25% [n ¼ 5 of 20] in BRAF-WT; P ¼ .083).
Across all lines of treatment, a total of 10 BRAF-MT patients received anti-EGFR mAbs; 7 as monotherapy and 3 in combination with chemotherapy and DCR was 10% (n ¼ 1 of 10). Notably, the best response achieved was stable disease in 1 patient, whereas the remaining 9 patients had progressive disease at first restaging. For the 1 patient who achieved stable disease, this lasted for 8 months using FOLFIRI-cetuximab in the second-line setting. In contrast, for BRAF-WT patients, across all lines of treatment, 25 of 57 RAS-WT patients received anti-EGFR mAbs; 14 as monotherapy and 11 in combination with chemotherapy and the DCR was 80% (n ¼ 20 of 25; Table 3 ).
Median duration of follow-up for BRAF-MT and WT patients was 19.6 and 23.9 months, respectively. mOS was significantly shorter for BRAF-MT patients at 18.2 months (95% CI, 14.1-25.3) compared with 41.1 months (95% CI, 29.7-50.9) in BRAF-WT patients (HR, 2.74; 95% CI, 1.60-4.70; P < .001; Figure 1 ). In the BRAF-WT group there was no significant difference in mOS 
Univariate Analysis
In univariate analysis (Table 4 ) BRAF-MT as well as BRAF-WT patients with a PS of 0 to 1 had improved survival compared with patients with poorer PS. For BRAF-MT patients a serum carcinoembryonic antigen of 50 nmol/L or presentation with synchronous metastases was associated with poorer survival. Furthermore, BRAF-WT patients with disease suitable for radical metastasectomy had significantly improved survival compared with patients with unresectable metastatic disease.
Discussion
In this study we reviewed the clinicopathological characteristics, treatment regimens, and survival outcomes of patients with BRAF-MT mCRC and compared with an age-and sex-matched population of BRAF-WT patients in a real world setting.
Our study, consistent with previous data has shown that BRAF-MT mCRC is associated with a number of characteristics including older age, female sex, right-sided primary tumor location, peritoneal metastases, and MMR deficiency. 9, 11, 12 It is recognized that disease stage, 4 age, 19, 20 and sex 21 might influence survival in CRC, but this can be through noncancer-related factors such as presence of comorbidities or delay in presentation rather than tumor biology. We therefore sought to investigate whether the poor prognosis of BRAF-MT patients is independent of such clinical characteristics and so matched for age and sex in the BRAF-WT control group. We restricted our analysis to patients with stage IV disease, because testing for BRAF status is not routine in earlier stage disease. We chose not to match for presence/absence of peritoneal metastases, which is commonly observed in BRAF-MT patients because we consider peritoneal metastases to be an inherent manifestation of BRAF-MT mCRC and a feature of its aggressive tumor biology. Our results confirm the significantly poorer survival of patients with BRAF-MT compared with BRAF-WT mCRC (18.2 vs. 41.1 months). This survival difference, observed despite matching for age and sex, supports the assertion that BRAF mutation is an independent marker of poor prognosis. This is in keeping with data from a combined analysis of randomized trials, in which BRAF-MT patients had a worse prognosis even after adjusting for clinicopathological features. 22 Our survival outcomes are slightly better than the mOS of 10 to 15 months reported for doublet chemotherapy in clinical trials 6, 13 and also compares favorably with the mOS of 19 months reported for triplet chemotherapy. 15 Although we acknowledge the limitations of data from our retrospective analysis, this shows the outcomes that can be achieved in a specialist tertiary center with close patient follow-up. Although we do not know if a more intense first-line triplet chemotherapy regimen would have improved our outcomes, sequential doublet chemotherapy remains a reasonable option bearing in mind the older age and potential for toxicities in this patient group. In this study the proportion of BRAF-MT and WT patients who received treatment at each line did not significantly differ, however in view of the small number of patients who received second-and third-line therapy this should be interpreted with caution. However, treatment benefit for BRAF-MT patients was greatest in the 
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Clinical Colorectal Cancer March 2018 -e73 first-line setting, where PFS was similar to that of BRAF-WT patients. Beyond first-line treatment, PFS declined with little clinical benefit in the third-line setting. This decline in treatment benefit after first-line progression is consistent with analysis of previous retrospective data. 23 One possible explanation for the poor prognosis of BRAF-MT patients is the development of mechanisms of resistance to chemotherapy after first-line treatment, more rapidly/ frequently than in BRAF-WT patients. More intensive treatment in the first-line setting, using triplet chemotherapy with or without anti-VEGF treatment thus might improve outcomes by exposing tumors to an active regimen when still sensitive to chemotherapy. Clinical trials on first-line triplet chemotherapy combined with anti-VEGF have reported survival advantage in BRAF-MT patients. 15 In the phase III TRIBE trial triplet chemotherapy was associated with a survival advantage in all molecular subgroups. 15 In the BRAF-MT subgroup a mOS of 19 months was achieved with FOLFOXIRI-bevacizumab compared with 10.8 months in the FOLFIRI-bevacizumab arm. The size of benefit with triplet chemotherapy was, however, the same across all molecular subgroups. The major concern with triplet chemotherapy is the potential for increased toxicity and poor tolerability, particularly because of the typically older age of BRAF-MT patients. In the TRIBE trial rates of Grade 3 or 4 neutropenia, diarrhea, stomatitis, and peripheral neuropathy were all significantly higher in the triplet chemotherapy arm. Although it is reassuring that treatment-related deaths were not significantly different, the patients' quality of life (QOL) data were not collected so the effect of toxicity on QOL is unclear. Furthermore, BRAF-MT patients made up only a small proportion of patients in the TRIBE trial (5.5% [n ¼ 28 of 508]). Entry into the trial was limited to patients aged younger than 76 years and with a PS of 0 if aged between 70 and 75 years. This resulted in a very selected population of good PS and younger patients. Thus, caution is needed when applying TRIBE trial results to the general population of BRAF-MT patients. In our study we did not treat any patients with triplet chemotherapy, because the findings of the TRIBE trial were not available when most patients were treated.
Response to anti-EGFR mAbs was poor for BRAF-MT patients in this study. Most BRAF-MT patients received anti-EGFR mAbs in the third-line setting and most had progressive disease (9 of 10 treated) by first restaging. Only 1 patient achieved stable disease and this was in combination with chemotherapy. The role of BRAF mutation as a negative predictive biomarker for anti-EGFR mAbs remains controversial and has been the subject of 2 recent metaanalyses. The first, by Pietrantonio et al analyzed 10 randomized trials and reported that anti-EGFR therapy did not benefit BRAF- It was also noteworthy that a proportion of BRAF-MT patients had a significantly better survival than the rest of the group. mOS was >25 months in 7 cases. These patients had clinical characteristics similar to the rest of the group and all had tumors with the V600E mutation. There is evidence that non-V600E BRAF mutations at codons 594 and 596 confer a better prognosis in mCRC. 25 Thus, in our study the reason for such improved survival in a subset of BRAF-MT patients is unclear, but similar findings have been observed by others 26 and this requires further investigation. BRAF mutation status alone should not preclude patients for treatment after first-line progression, because a proportion will continue to derive benefit. Indeed, a recent large combined analysis of 3 clinical trials reported 24% of BRAF-MT mCRC patients had a post first-line progression survival of >6 months. 23 Careful assessment and monitoring of patients after first-line progression is required to ensure appropriate selection for subsequent treatments.
Of particular interest is the increased rates of MMR deficiency in BRAF-MT tumors (30% in this series), which results in microsatellite instability and hypermutability (MSI-H). This association is recognized in the consensus on molecular subtypes of CRC (CMS), where CMS1 tumors are MSI-H, hypermethylated, and enriched for BRAF mutation. 27 These tumors are related to serrated polyps 28 in their developmental history and characterized by a cytosinephosphate-guanine island methylator phenotype. 29 Consequently epigenetic methylation of the MutL homolog 1 (MLH1) gene is the most common cause of sporadic MSI-H status in CRC. In the metastatic setting, patients with MSI-H CRC have a poorer prognosis compared with microsatellite stable cases, however, a large pooled analysis of 4 phase III studies reported that the poorer prognosis of MSI-H mCRC is driven by the higher proportion of BRAF-MT patients in this group. 30 Because of the resultant DNA replication errors in MSI-H tumors, a greatly elevated mutational burden is seen, leading to expression of neoantigens, which might be recognized by the host immune system. The tumor microenvironment of MSI-H tumors is highly infiltrated by tumor infiltrating lymphocytes 31 and there is upregulation of programmed cell death protein 1/ programmed death ligand 1 (PD1/PDL1) immune checkpoints. 32 This provides the rationale for use of immune checkpoint inhibitors in this setting. In a proof of concept phase II study, PD1 blockade with pembrolizumab resulted in a clinically significant response rate of 40% (n ¼ 4 of 10) in patients with previously treated mCRC. 33 More recently, another phase II study investigated the anti-PD1 drug nivolumab in 74 patients with advanced MSI-H CRC who had received at least 1 previous line of chemotherapy. 34 At a median follow-up of 12 months, a 
Conclusion
This study confirms the poor prognosis of patients with BRAF-MT mCRC, which was observed even after matching for age and sex. In this tertiary center cohort, a mOS of 18.2 months was achieved using sequential doublet chemotherapy with or without biologic agents. After initially promising PFS with first-line therapy there was a subsequent decline in the second-and third-line setting. Clinical benefit from systemic therapy appears to be greatest in the first-line setting in this population, where there might be a window of opportunity for potentially more intensive treatment. Anti-EGFR mAbs did not appear to benefit BRAF-MT mCRC patients in this study. Recruitment to suitable clinical trials is recommended to improve outcomes in this poor-prognosis patient group. deficiency, right-sided primary tumors, peritoneal metastases, and lower rates of oligometastatic disease. BRAF-MT mCRC patients have a significantly poorer prognosis compared with BRAF-WT patients, even when matched for age and sex.
Clinical Practice Points
The poor prognosis appears to be related to reduced PFS and chemosensitivity after first-line progression. Sequential doublet chemotherapy remains a reasonable option. A proportion of patients continue to benefit from chemotherapy after first-line progression. BRAF mutation testing should be offered at the time of diagnosis of mCRC. Knowledge of BRAF status helps guide prognosis and allows early recruitment to clinical trials.
